1-3 of 3
Guopan Yu, MD, PhD
Close
Sort by
Journal Articles

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hongying Zhang, MD, PhD, Charlie Ly, BS, Bin Yuan, Vivian Ruvolo, MS, Sujan Piya, PhD, Seemana Bhattacharya, PhD, Qi Zhang, PhD, Gautam Borthakur, MD, Venkata Lokesh Battula, PhD, Marina Y. Konopleva, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2635.
https://doi.org/10.1182/blood-2018-99-116643
Published: 2018
Journal Articles

CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status

Guopan Yu, MD, PhD, Weiguo Zhang, MD PhD, Charlie Ly, BS, Hongying Zhang, MD, William Rice, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4629.
https://doi.org/10.1182/blood.V130.Suppl_1.4629.4629
Published: 2017
Journal Articles

The Pan-FLT3/BTK Multi-Kinase Inhibitor CG '806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

Charlie Ly, BS, Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hong Mu, MD PhD, Hongying Zhang, MD, William Rice, PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3348.
https://doi.org/10.1182/blood.V130.Suppl_1.3348.3348
Published: 2017